Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Vaginal cancer Indication Strategy Report 2026: PD-1, Trials and Deals
24 July 2026
2026 Vaginal cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Small cell carcinoma of the ovary hypercalcemic type Indication Strategy Report 2026: SMARCA4, Trials and Deals
24 July 2026
2026 Small cell carcinoma of the ovary hypercalcemic type strategy: epidemiology, SMARCA4 biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Uterine serous carcinoma Indication Strategy Report 2026: HER2, Trials and Deals
24 July 2026
2026 Uterine serous carcinoma strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Sertoli-Leydig cell tumor Indication Strategy Report 2026: DICER1, Trials and Deals
24 July 2026
2026 Sertoli-Leydig cell tumor strategy: epidemiology, DICER1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Ovarian sex cord stromal tumor Indication Strategy Report 2026: VEGFR, Trials and Deals
24 July 2026
2026 Ovarian sex cord stromal tumor strategy: epidemiology, VEGFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pancreatic cystic neoplasm Indication Strategy Report 2026: KRAS, Trials and Deals
24 July 2026
2026 Pancreatic cystic neoplasm strategy: epidemiology, KRAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Adult granulosa cell tumor Indication Strategy Report 2026: FOXL2, Trials and Deals
24 July 2026
2026 Adult granulosa cell tumor strategy: epidemiology, FOXL2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Intraductal papillary mucinous neoplasm Indication Strategy Report 2026: KRAS, Trials and Deals
24 July 2026
2026 Intraductal papillary mucinous neoplasm strategy: epidemiology, KRAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Solid pseudopapillary neoplasm of pancreas Indication Strategy Report 2026: CTNNB1, Trials and Deals
24 July 2026
2026 Solid pseudopapillary neoplasm of pancreas strategy: epidemiology, CTNNB1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pancreatic adenosquamous carcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
24 July 2026
2026 Pancreatic adenosquamous carcinoma strategy: epidemiology, KRAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Anal adenocarcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
24 July 2026
2026 Anal adenocarcinoma strategy: epidemiology, EGFR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
HER2-positive colorectal cancer Indication Strategy Report 2026: HER2, Trials and Deals
24 July 2026
2026 HER2-positive colorectal cancer strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.